<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827540</url>
  </required_header>
  <id_info>
    <org_study_id>TBR 652-1-110</org_study_id>
    <nct_id>NCT01827540</nct_id>
  </id_info>
  <brief_title>Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG &amp; on a Single Dose of Midazolam</brief_title>
  <official_title>A Phase I, Multiple-Dose, Open-Label, Crossover Study in Healthy Subjects to Assess the Effect of Dolutegravir (DTG) on the Pharmacokinetics (PK) of Cenicriviroc (CVC) and the Effect of CVC on the PK of DTG and on a Single Dose of Midazolam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tobira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tobira Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and
      without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

        -  To evaluate the steady-state PK of CVC administered with and without DTG .

        -  To evaluate the steady-state PK of DTG administered with and without CVC .

        -  To evaluate the PK of a single dose of Midazolam administered with and without steady
           state CVC when both are administered orally.

      Secondary Objectives

        -  To evaluate the safety and tolerability of CVC administered with and without DTG.

        -  To evaluate the safety and tolerability of CVC administered with and without Midazolam.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment of Cenicriviroc</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, &amp; 24 hours postdose on Days 10 and 20</time_frame>
    <description>PK profile will be calculated based on CVC exposure. Trough (predose) CVC plasma samples will be obtained prior to dosing on Days 2-9 &amp; 12-19.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment of Dolutegravir</measure>
    <time_frame>0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, &amp; 24 hours postdose on Days 10 and 20</time_frame>
    <description>PK profile will be calculated based on DTG exposure. Trough (predose) DTG plasma samples will be obtained prior to dosing on Days 2-9 &amp; 12-19.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment of Midazolam and alpha-hydroxymidazolam</measure>
    <time_frame>0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 &amp; 18 hours postdose on Day -1 and Day 9</time_frame>
    <description>PK profile will be calculated (Group 1 only) based on plasma midazolam &amp; alpha-hydroxymidazolam exposure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Participants will be followed upon taking first dose of study medication until the follow-up visit, an expected average of 5 weeks</time_frame>
    <description>Physical examinations, vital signs, ECGs, clinical laboratory tests, and AEs or serious AEs (SAEs) will be assessed at specified time points according to the Schedule of Procedures in the protocol. In addition, arterial oxygen saturation will be monitored by pulse oximetry for at least 2 hours after administration of midazolam on Days -1 and 9 in Group 1.
For both groups, a final follow-up visit will occur 14 days (±3 days) after the last dose of study medication, or at the time of early termination (if applicable) to evaluate any remaining safety issue(s).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV-infection/AIDS</condition>
  <arm_group>
    <arm_group_label>Cenicriviroc + Midazolam, and CVC + DTG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 &amp; w/ CVC 150mg on Day 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir , and DTG + CVC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenicriviroc</intervention_name>
    <arm_group_label>Cenicriviroc + Midazolam, and CVC + DTG</arm_group_label>
    <arm_group_label>Dolutegravir , and DTG + CVC</arm_group_label>
    <other_name>CVC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <arm_group_label>Cenicriviroc + Midazolam, and CVC + DTG</arm_group_label>
    <arm_group_label>Dolutegravir , and DTG + CVC</arm_group_label>
    <other_name>DTG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Cenicriviroc + Midazolam, and CVC + DTG</arm_group_label>
    <other_name>Dormicum</other_name>
    <other_name>Hypnovel</other_name>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed voluntary consent

          2. Adult male and female healthy volunteers

          3. Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2.

          4. Be in good general health with no clinically relevant abnormalities

          5. Agree to comply with study procedures and restrictions

        Exclusion Criteria:

          1. Any disease or condition that might affect drug absorption, metabolism, or excretion,
             or clinically significant cardiovascular as determined by investigator

          2. History of stomach or intestinal surgery, except for fully healed appendectomy and/or
             cholecystectomy which will be allowed

          3. Clinically significant illness or clinically significant surgery within 4 weeks before
             the administration of study medication

          4. Known or suspected hypersensitivity or allergic reaction to any of the components of
             CVC or DTG tablets, or midazolam syrup

          5. Serum ALT, AST, or bilirubin values greater than or equal to Division of Acquired
             Immunodeficiency Syndrome (DAIDS) grade 1 at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audrey Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SeaView Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SeaView Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>Cenicriviroc (CVC)</keyword>
  <keyword>Dolutegravir (DTG)</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Healthy Subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>TAK-652</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

